Merck Healthcare

How did a VCR lead to Arvind Rajpal’s career in R&D? 📼 Learn more about our Head of Discovery and Development Technologies (DDTech), and the exciting things that our DDTech team is working on today, in this video. #RDInMotion #ResearchAndDevelopment #AsOneForPatients

Patients living with rare tumors often carry the care coordination burden themselves: multiple specialists, complex regimens, and retelling their story at every new appointment. Merck is collaborating with Microsoft for Healthcare, NVIDIA Healthcare and Dawn Health to develop a new model of patient support, one designed to be more individualized, responsive and continuously available, no matter how complex the treatment journey. This is not a new app layered on top of existing support. It's a shift toward one connected ecosystem, bringing together pharmaceutical and clinical expertise, enterprise cloud and AI services, and digital health product design. Every interaction is grounded in clinically reviewed content, with defined escalation pathways and full traceability, so human support from a nurse or healthcare provider remains available exactly where it's needed. We're sharing more from NVIDIA GTC Berlin, where this collaboration reflects what's possible when healthcare expertise and enterprise AI infrastructure are brought together with the patient need, not the technology, as the starting point. Hear more from Emre Ozcan, PhD, Alexander Mandix Hansen (CEO, Dawn Health) and Rory Kelleher (Global Head of Business Development, Healthcare and Life Sciences, NVIDIA) Read the full announcement: https://lnkd.in/e9SVuTSX #HighTouchHighTech #AsOneForPatients

Some of the most important challenges patients face never show up in a scan. I remember my first conversations with people living with rare tumors. We talked about pain, mobility, the ability to work and the uncertainty of living with a condition that few people truly understand. But something else stayed with me: For many patients, the hardest moments happen between appointments. When symptoms change, when side effects become difficult to manage or when they simply need an answer from someone who understands their condition. We have made extraordinary progress in developing medicines that can change the course of a disease. But bringing an innovative medicine to patients is only part of realizing its full potential. I believe the next frontier in healthcare is connecting innovation in medicines with innovation in how we deliver care, so that scientific progress translates into meaningful outcomes in patients' everyday lives; that requires a different kind of collaboration. Today, I'm proud to share our work with NVIDIA Healthcare , Microsoft for Healthcare and Dawn Health to explore a new model of AI-enabled, integrated patient support for people living with rare tumors. We are bringing together pharmaceutical and clinical expertise, advanced AI, cloud technology and digital health capabilities to work toward something fundamentally different. A model where patients can access reliable, personalized support when they need it. Where their needs can be better understood as they evolve. And where technology helps connect them with human expertise at the moments it matters most. Not AI replacing healthcare professionals, but helping them deliver more informed, timely and personalized support. No single industry can build this future alone. Pharmaceutical companies bring deep scientific and clinical expertise, an understanding of medicines and their real-world use. Technology companies bring capabilities that can help us rethink how support is delivered. Digital health partners turn those possibilities into experiences patients can use. The real opportunity lies in bringing these strengths together, responsibly, and translating them into meaningful patient value. We are still at the beginning, with important questions to answer and much to prove. But I keep coming back to those first patient conversations. Success should not only be about what we build or how advanced the technology becomes. It should ultimately be about whether patients can better manage their disease, navigate treatment and live their lives. Because the value of medical innovation is ultimately realized in the lives of the people it is meant to help. #HighTouchHighTech #AsOneForPatients

Prediabetes serves as an early warning sign that blood sugar levels are higher than ideal, with the possible progression to Type 2 diabetes if not addressed. Don’t wait for a more serious diagnosis - take our free online risk assessment test. It’s quick, easy, and could be your first step toward a healthier future. Take the test | Are you at risk for Diabetes? #AsOneForPatients #WinningMoves

Want to understand diabetes better before your doctor's appointment? Good preparation helps you manage blood sugar effectively. Watch to learn what you should bring to your appointment. Take the test | Are you at risk for Diabetes? #AsOneForPatients #WinningMoves

Behind every data point is a person waiting for better treatment options, better outcomes, and more time with the people they love. As we prepare for ESMO - European Society for Medical Oncology 2026, our teams remain focused on advancing research that may help address unmet needs across cancer and rare tumors. In this video, Victoria Zazulina shares what drives our work and why the science we'll present at ESMO matters beyond the numbers. Learn more about the latest research, data, and innovation we will be presenting in our ESMO 2026 press release: https://lnkd.in/eCYJUpc7 #AsOneForPatients #ESMO2026